Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
* This is the eighth indication for DUPIXENT® in Canada and its first in gastroenterology. MISSISSAUGA, ON, May 4, 2023 /CNW/ - sanofi-aventis Canada Inc. (Sanofi Canada) is pleased to announce that...
* Approval marks second first-line indication in NSCLC and fifth indication for Libtayo® in Canada TORONTO, May 1, 2023 /CNW/ - sanofi-aventis Canada Inc. (Sanofi Canada) and Regeneron are pleased to ...
BEYFORTUS™ (nirsevimab) is the first and only single-dose immunization designed for the prevention of RSV disease in newborns and infants, including those born healthy, at term or preterm, or with...
* This is the seventh indication for Dupixent® in Canada TORONTO, April 20, 2023 /CNW/ - Sanofi-aventis Canada Inc. (Sanofi Canada) announced today that Health Canada has issued a Notice of...
Nirsevimab is the first investigational long-acting antibody designed for all infants to help protect against respiratory syncytial virus (RSV) throughout their first RSV season with a single dose...
Reinforces Sanofi Canada's commitment to inclusion and diversity, STEM equity and scientific innovation LAVAL, QC, Jan. 25, 2022 /CNW/ - For the second year in a row, Sanofi Canada has been named one ...
LAVAL, QC, Dec. 9, 2021 /CNW/ - Marking 100 years since the discovery of insulin at Connaught Laboratories, the predecessor of Sanofi Canada, the researchers responsible for the diabetes drug –...
MISSISSAUGA, ON, Nov. 15, 2021 /CNW/ - Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for the long-term treatment of patients older than 6 months of age with late-onset...
Ahead of World Diabetes Day, Sanofi Canada releases market research that explores the care journey for Canadians living with diabetes LAVAL, QC, Nov. 10, 2021 /CNW/ - Forty per cent of Canadians...
The approval is based on data from the open-label, multi-center, non-randomized Study 16201 MISSISSAUGA, ON, Oct. 29, 2021 /CNW/ - Libtayo® (cemiplimab) is now approved in Canada for the treatment of ...
The approval is based on data from the randomized, open-label, multi-center Study 16241 MISSISSAUGA, ON, Oct. 29, 2021 /CNW/ - Libtayo® (cemiplimab) is now approved in Canada for the first-line...
The approval is based on data from the Phase 3 IKEMA study.1,2 Multiple myeloma (MM) is the third most common blood cancer in Canada, with an estimated 3300 new cases diagnosed in 2019.3 MISSISSAUGA, ...
Recommendation supported by multiple clinical trials that demonstrated a reduced frequency of asthma exacerbations compared to placebo, and a reduction in the need for oral corticosteroids in oral...
* Multiple Canadian research studies were presented at the 81st Annual American Diabetes Association Scientific Sessions to identify optimal therapies for sustained diabetes management and remission. ...
DUPIXENT® is approved by Health Canada for use in moderate-to-severe atopic dermatitis, severe chronic rhinosinusitis with nasal polyposis and severe asthma.1 The pre-filled pen offers an additional...
Inaugural Sanofi Biogenius Grant awarded to four diverse secondary schools across Canada to revitalize science education for their students. Driving towards Science, Technology, Engineering &...
DUPIXENT® is the only biologic medicine approved by Health Canada to treat moderate-to-severe atopic dermatitis (AD). Public reimbursement under the Régie de l'assurance maladie du Québec will now...
* DUPIXENT® is the only biologic medicine approved by Health Canada to treat moderate-to-severe atopic dermatitis. * Public reimbursement under the Ontario Exceptional Access Program and the New...
Sanofi announces investment of approximately $925 million (CAD) to build a new vaccine facility in Toronto to increase supply of its differentiated influenza vaccines in Canada, the United States,...
DUPIXENT® is the only biologic medicine approved to treat atopic dermatitis for this patient population. Fifth indication for DUPIXENT® in Canada following approvals for moderate-to-severe atopic...
Sanofi believes that all students deserve equal opportunities to be innovators, no matter their socio-economic background, cultural or ethnic origin, sexual orientation, gender identity and/or...
Reinforces Sanofi Canada's strong commitment to inclusion and diversity in the workplace, employee professional growth and fostering a positive and meaningful work environment. LAVAL, QC, Jan. 26,...
Only biologic approved in Canada to treat severe asthma with type 2 / eosinophilic phenotype, or oral corticosteroid-dependent asthma Fourth indication for DUPIXENT® in Canada following approvals for ...
Signed agreements relate to vaccine candidate using Sanofi's recombinant protein-based technology combined with GSK's pandemic adjuvant Both companies are committed to making their COVID-19 vaccine...
First biologic approved in Canada for adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP)1 Third indication for DUPIXENT® in Canada following moderate-to-severe atopic dermatitis...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.